DE3783958T2 - Verzoegerte abgabe von makromolekularen polypeptiden. - Google Patents

Verzoegerte abgabe von makromolekularen polypeptiden.

Info

Publication number
DE3783958T2
DE3783958T2 DE8787304570T DE3783958T DE3783958T2 DE 3783958 T2 DE3783958 T2 DE 3783958T2 DE 8787304570 T DE8787304570 T DE 8787304570T DE 3783958 T DE3783958 T DE 3783958T DE 3783958 T2 DE3783958 T2 DE 3783958T2
Authority
DE
Germany
Prior art keywords
delayed delivery
macromolecular polypeptides
macromolecular
polypeptides
micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787304570T
Other languages
English (en)
Other versions
DE3783958D1 (de
DE3783958T3 (de
Inventor
Deborah Ann Eppstein
Brian Bloor Schryver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25348017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3783958(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of DE3783958D1 publication Critical patent/DE3783958D1/de
Publication of DE3783958T2 publication Critical patent/DE3783958T2/de
Application granted granted Critical
Publication of DE3783958T3 publication Critical patent/DE3783958T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
DE3783958T 1986-05-23 1987-05-22 Verzögerte Abgabe von makromolekularen Polypeptiden. Expired - Fee Related DE3783958T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/866,625 US4962091A (en) 1986-05-23 1986-05-23 Controlled release of macromolecular polypeptides

Publications (3)

Publication Number Publication Date
DE3783958D1 DE3783958D1 (de) 1993-03-18
DE3783958T2 true DE3783958T2 (de) 1993-06-09
DE3783958T3 DE3783958T3 (de) 2003-08-07

Family

ID=25348017

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3783958T Expired - Fee Related DE3783958T3 (de) 1986-05-23 1987-05-22 Verzögerte Abgabe von makromolekularen Polypeptiden.

Country Status (10)

Country Link
US (1) US4962091A (de)
EP (1) EP0251476B2 (de)
JP (1) JP2594560B2 (de)
AT (1) ATE85214T1 (de)
AU (1) AU608225B2 (de)
CA (1) CA1293443C (de)
DE (1) DE3783958T3 (de)
ES (1) ES2039437T5 (de)
HK (1) HK38997A (de)
NZ (1) NZ220403A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932603A1 (de) * 1999-07-13 2001-01-25 Gruenenthal Gmbh Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5288487A (en) * 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CH681425A5 (de) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5252342A (en) * 1990-03-05 1993-10-12 The Regents Of The University Of California Enhancement of anti-neoplastic drug efficacy using EGF
US5597798A (en) * 1990-03-05 1997-01-28 The Regents Of The University Of California Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
EP0528978B1 (de) * 1990-05-16 2002-10-16 Southern Research Institute Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
US6517859B1 (en) * 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IL99497A (en) * 1990-10-01 1997-03-18 Res Dev Foundation Synergistic compositions comprising tnf and il-4
WO1992006112A1 (en) * 1990-10-09 1992-04-16 Sri International Activated ctap and analogs thereof and their use
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2097426A1 (en) * 1990-11-30 1992-05-31 Bruce M. Cameron, Sr. Method for the diagnosis of chronic lower back and cervical pain
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
WO1992012726A1 (en) * 1991-01-16 1992-08-06 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
WO1992019263A1 (en) * 1991-04-24 1992-11-12 The United States Of America, As Represented By The Secretary Of The Army Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
JPH07507768A (ja) * 1992-03-12 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド Ａｃｔｈ含有マイクロスフェアの制御放出
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
MX9301821A (es) * 1992-03-30 1994-03-31 Alza Corp Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US7105158B1 (en) * 1992-11-16 2006-09-12 The Corporation Of Mercer University Methods of administering microencapsulated materials for immune modulated diseases
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
RU2143889C1 (ru) * 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
AU6637394A (en) * 1993-04-19 1994-11-08 Medisorb Technologies International L.P. Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
AU7846894A (en) * 1993-09-29 1995-04-18 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
JPH07100178A (ja) * 1993-10-01 1995-04-18 Sadako Ueda 天然炭酸カルシウム入浴剤
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
CA2175049A1 (en) * 1993-10-28 1995-05-04 Timothy Ringeisen Improved process and device for treating and healing a bone void
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
CN1120809A (zh) * 1993-12-23 1996-04-17 Gff工业方向促进研究公司 增强免疫应答的方法
BR9507313B8 (pt) * 1994-04-08 2016-06-07 Atrix Lab Inc composição líquida de liberação adequada para a formação de um implante de liberação controlada, sistema polimérico, curativo fílmico microporoso biodegradável, e, precursor de um implante de liberação controlada para a implantação em um indivíduo
US5981825A (en) 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
US5681568A (en) * 1994-08-19 1997-10-28 Cambridge Neuroscience, Inc. Device for delivery of substances and methods of use thereof
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
JPH08215516A (ja) * 1995-02-10 1996-08-27 Hiroshi Kaneko 浴槽水の浄化・活性化フィルタ−
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
EP0765660A3 (de) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Mikrokapseln enthaltend 2-Piperazinon-1-essigsäure Verbindungen
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6902584B2 (en) 1995-10-16 2005-06-07 Depuy Spine, Inc. Bone grafting matrix
US5776193A (en) 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US6190702B1 (en) 1996-03-28 2001-02-20 Takeda Chemical Industries, Ltd. Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
DE69705746T2 (de) * 1996-12-20 2001-10-31 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
CA2315537A1 (en) 1997-12-16 1999-06-24 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
WO1999048519A1 (en) 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
AU6027899A (en) * 1998-09-02 2000-03-21 Point Biomedical Corporation Local delivery of medications to the heart
CA2350638C (en) * 1998-09-11 2009-11-24 Gerhard Schmidmaier Biologically active implants coated with a biodegradable polymer
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
DE10008880A1 (de) * 1999-02-19 2000-08-24 Bioserv Ag Bioabbaubare Komposite zur Herstellung von Mikrokapseln
EP1161257A2 (de) 1999-03-17 2001-12-12 Novartis AG Tgf-beta enthaltende pharmazeutische zusammensetzungen
DE60003803T2 (de) * 1999-04-16 2004-06-03 Novo Nordisk A/S Trockene formbare arzneistoffformulierung
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US7678087B2 (en) * 1999-09-29 2010-03-16 Heska Corporation Equine intranasal delivery system
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
EP1586329A1 (de) * 2000-02-08 2005-10-19 Allergan, Inc. Pharmazeutische Zusammensetzungen mit botulinum Toxin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
WO2001068158A1 (en) 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6927223B1 (en) 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
AU2001281729A1 (en) * 2000-07-14 2002-01-30 Novo-Nordisk A/S Method of moulding a pharmaceutical composition in a packaging material
ES2292634T3 (es) 2000-12-21 2008-03-16 Alrise Biosystems Gmbh Procedimiento de transicion de fase inducida para la produccion de microparticulas que contienen agentes hidrofilos activos.
IL156682A0 (en) * 2000-12-29 2004-01-04 Pbl Biomedical Lab Controlled release systems for polymers
CN1520313A (zh) * 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
AU2002324447B2 (en) 2001-06-22 2006-06-29 Durect Corporation Zero-order prolonged release coaxial implants
DE10146251A1 (de) * 2001-09-20 2003-04-17 Gruenenthal Gmbh Vorrichtung zur Herstellung eines pharmazeutischen Films
MXPA04004730A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US7332276B2 (en) 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
DK2561860T3 (en) 2002-05-31 2018-04-30 Titan Pharmaceuticals Inc Implantable polymer device for prolonged release of buprenorphine
AU2003251829B2 (en) 2002-07-09 2009-12-10 Radical Therapeutix Method to inhibit ischemia and reperfusion injury
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
AU2003297282A1 (en) * 2002-11-14 2004-06-15 Cornell Research Foundation, Inc. Protection of cardiac myocardium
EP2258724A1 (de) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
US20070026069A1 (en) * 2003-03-28 2007-02-01 Shastri Venkatram P Biommetic hierarchies using functionalized nanoparticles as building blocks
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
EP1638595B1 (de) * 2003-06-20 2013-03-20 Ares Trading S.A. Gefriergetrocknete fsh / lh formulierungen
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses
BRPI0414093A (pt) * 2003-09-05 2006-10-31 Scripps Res Insittute produtos de ozonização de colesterol para o tratamento e prevenção de ateroesclerose e/ou doenças cardiovasculares
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
US7164008B2 (en) * 2003-11-17 2007-01-16 University Of Iowa Research Foundation Isolated complexes of endotoxin and MD-2
EP1723422A2 (de) * 2004-03-05 2006-11-22 The Scripps Research Institute Glycan-mikroarray mit hohem durchsatz
US8613934B2 (en) * 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
CA2563329C (en) 2004-04-30 2016-01-26 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20060194726A1 (en) * 2004-05-25 2006-08-31 Rueger David C Methods of treating cartilage defects
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
CN101437834B (zh) * 2004-07-19 2012-06-06 贝勒医学院 细胞因子信号转导调节剂的调节和用于免疫治疗的应用
NZ553494A (en) 2004-08-18 2010-07-30 Novabiotics Ltd Antimicrobial peptides comprising an arginine- and/or lysine-containing motif
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US7413729B2 (en) * 2005-01-13 2008-08-19 University Of Iowa Research Foundation Sialic acid permease system
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
EP1976863B1 (de) 2005-12-22 2012-12-12 Novabiotics Limited Cyclische antimikrobielle peptide
WO2007095350A2 (en) * 2006-02-15 2007-08-23 Yale University Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
US8088396B2 (en) * 2006-03-01 2012-01-03 University Of Iowa Research Foundation Isolated complexes of endotoxin and modified MD-2
US20070265170A1 (en) * 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer
US8137682B2 (en) * 2006-09-20 2012-03-20 University Of Iowa Research Foundation Isolated complexes of covalently cross-linked endotoxin and modified MD-2
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
EP2136832B1 (de) 2007-03-26 2015-09-02 General Regeneratives Limited Verfahren zur förderung des schutzes und der regeneration von knochenmark mit cxcl9 und anti-cxcl9-antikörpern
WO2008150897A2 (en) 2007-05-31 2008-12-11 University Of Iowa Research Foundation Reduction of off-target rna interference toxicity
WO2008150477A2 (en) 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine as a therapeutic agent
US8324369B2 (en) * 2007-11-30 2012-12-04 Baylor College Of Medicine Dendritic cell vaccine compositions and uses of same
TWI352717B (en) * 2007-12-11 2011-11-21 Ind Tech Res Inst A tenacity adjuster, a biodegradable material comp
WO2009089027A1 (en) * 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
AR067447A1 (es) * 2008-07-03 2009-10-14 Monte Verde S A Un procedimiento para preparar una composicion farmaceutica que contiene los proincipios activos glucosamina y meloxicam y el uso de dicha asociacion para el tratamiento de patologias degenerativas osteo-articulares
US20110150765A1 (en) 2008-10-31 2011-06-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Frozen compositions and methods for piercing a substrate
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8563012B2 (en) 2008-10-31 2013-10-22 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8518031B2 (en) 2008-10-31 2013-08-27 The Invention Science Fund I, Llc Systems, devices and methods for making or administering frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100178038A1 (en) * 2009-01-12 2010-07-15 Mediatek Inc. Video player
WO2011038002A1 (en) 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
US8632839B2 (en) * 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
EP2468269A1 (de) 2010-11-26 2012-06-27 Universitätsklinikum Münster Nitridoxidspender bei der Behandlung von Nitridoxidmangel-induzierten Störungen der Hirnmikrozirkulation
WO2012076842A1 (en) 2010-12-09 2012-06-14 University Of Durham Synthetic retinoids for control of cell differentiation
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
CA2827380C (en) 2011-02-12 2020-08-25 University Of Iowa Research Foundation Therapeutic nucleic acids
CA2846486C (en) 2011-07-12 2019-08-20 Philadelphia Health & Education Corporation Novel clostridium difficile dna vaccine
WO2013013178A1 (en) 2011-07-21 2013-01-24 Kansas State University Research Foundation Sesquiterpenes for antifungal applications
WO2014011663A1 (en) 2012-07-09 2014-01-16 Board Of Trustees Of Michigan State University Inhibitors of bacterial diguanylate cyclase
WO2014066498A1 (en) 2012-10-23 2014-05-01 Vivek Mittal Treatment of metastatic breast cancer
DK2925297T3 (en) * 2012-11-02 2017-10-02 Cytuvax COMPOSITION COMPREHENSIVE CYTOCHINE MACROAGGERATES
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
US10157261B2 (en) 2013-08-09 2018-12-18 The Scripps Research Institute Transcriptome-wide design of selective, bioactive small molecules targeting RNA
EP3039126B1 (de) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Kleinmolekülige zelluläre reprogrammierung zur erzeugung neuronaler zellen
EP3043822A1 (de) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Zusammensetzungen zur herstellung von kardiomyozyten
EP3146051B8 (de) 2014-05-20 2019-11-27 University of Iowa Research Foundation Therapeutische verbindungen für huntington-krankheit
WO2016040347A2 (en) 2014-09-08 2016-03-17 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
US9758781B2 (en) 2014-09-30 2017-09-12 University Of Iowa Research Foundation Methods to prevent and treat autosomal dominant non-syndromic hearing loss
EP3261675A1 (de) 2015-02-25 2018-01-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Sialylierungserhöhende therapien für erkrankungen im zusammenhang mit oxidativem stress
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
WO2016199146A1 (en) * 2015-06-09 2016-12-15 B. G. Negev Technologies And Applications Ltd A controlled release system for pulmonary delivery of surfactant protein d
WO2017027280A1 (en) 2015-08-07 2017-02-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Chemical reprogramming to generate neuronal cells
RU2759945C2 (ru) * 2015-12-17 2021-11-19 Лайф Текнолоджиз Корпорейшн Гранулы, используемые в клеточной культуре, и способы их получения
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
EP3481374A1 (de) 2016-07-08 2019-05-15 The Scripps Research Institute Desensibilisierung von mastzellen durch co-präsentation von antigenen mit hochaffinen mastzellen-siglec-liganden
WO2018224813A1 (en) 2017-06-06 2018-12-13 Novabiotics Limited Use of cysteamine compositions
US11154606B2 (en) 2017-07-05 2021-10-26 Arizona Board Of Regents On Behalf Of Arizona State University Vaccine for prevention of necrotic enteritis in poultry
CA3069515A1 (en) 2017-07-10 2019-01-17 Cornell University Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
WO2019018666A1 (en) 2017-07-21 2019-01-24 University Of North Dakota INHIBITION OF FAK-AKT INTERACTION TO INHIBIT METASTASES
SG11202102058UA (en) 2018-08-30 2021-03-30 Tenaya Therapeutics Inc Cardiac cell reprogramming with myocardin and ascl1
CA3116637A1 (en) 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
US20220089670A1 (en) 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
US20230037822A1 (en) 2019-10-28 2023-02-09 The Scripps Research Institute Immune cell receptor antibodies conjugated to high affinity siglec-ligands
US20230053688A1 (en) 2020-01-10 2023-02-23 Cornell University Methods to alter latency in ebv+ malignancies
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2022159496A2 (en) 2021-01-19 2022-07-28 The J. David Gladstone Institutes, A Testamentary Trust Under The Will Of J. David Gladstone Gene activation targets for enhanced human t cell function
WO2023250249A1 (en) 2022-06-23 2023-12-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4512972A (en) * 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932603A1 (de) * 1999-07-13 2001-01-25 Gruenenthal Gmbh Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren

Also Published As

Publication number Publication date
JP2594560B2 (ja) 1997-03-26
EP0251476B2 (de) 2002-11-27
EP0251476A1 (de) 1988-01-07
AU608225B2 (en) 1991-03-28
NZ220403A (en) 1990-06-26
ATE85214T1 (de) 1993-02-15
US4962091A (en) 1990-10-09
ES2039437T5 (es) 2003-06-16
DE3783958D1 (de) 1993-03-18
DE3783958T3 (de) 2003-08-07
EP0251476B1 (de) 1993-02-03
CA1293443C (en) 1991-12-24
HK38997A (en) 1997-04-04
ES2039437T3 (es) 1993-10-01
JPS632930A (ja) 1988-01-07
AU7333287A (en) 1987-11-26

Similar Documents

Publication Publication Date Title
DE3783958T2 (de) Verzoegerte abgabe von makromolekularen polypeptiden.
DE3750619D1 (de) System zur Abgabe von Arzneistoffen.
DE58904179D1 (de) Septum fuer implantierbare vorrichtungen zur abgabe von wirkstoffen.
DK288987A (da) Et afgivelsessystem til doseringsformerne forhalet afgivelse, samt dettes fremstilling
DE68910833D1 (de) Polylactid-zubereitungen.
DE3586713T2 (de) Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
DE68908456T2 (de) Matrix zur Wirkstoffabgabe.
DE68901986D1 (de) Turbomolekularpumpe und deren betriebsverfahren.
DE68910867D1 (de) Matrix für die transdermale Abgabe von Arzneimitteln.
DE3769379D1 (de) Entzuendungshemmende wirkstoffe, pharmazeutische zusammensetzungen und verfahren zur bekaempfung von entzuendungen.
DE3771272D1 (de) Pulsierendes arzneistoffabgabesystem.
ATE64529T1 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
DK618186D0 (da) Konfektureindgiftssystem til aktive stoffer
NO882897L (no) Avleveringssystem for legemidler.
DK304485D0 (da) Faste laegemiddelpraeparater med dihydropyridiner samt fremstilling deraf
DE3880227D1 (de) Vorbeugung der nachoxidaton von methacrolein.
DK642588A (da) Indanderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
NO903844D0 (no) Medikamentavgivelsesblandinger basert paa biologiske celler eller komponenter derav og fremgangsmaater.
DE69002034T2 (de) Vorrichtung mit gesteuerter Wirkstoffabgabe.
NO892764L (no) Medikamentell administreringsform for droevtyggere.
FI890729A0 (fi) Anordning foer montering av delarna i en vinkelremledning.
DE3869268D1 (de) Vorrichtng mit verzoegerter abgabe von arzneimitteln mit donnanartiger modulation von geladenen unloeslichen harzen.
DE3788338D1 (de) Vorbehandlungswirkstoff zur perkutanen verabreichung.
ES2019634B3 (es) Terapia con clorfeniramina.
IT8420407A0 (it) Composizione anti-acne a base di tiossolone e di almeno un altro principio attivo.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: SYNTEX (U.S.A.) LLC, PALO ALTO, CALIF., US

8339 Ceased/non-payment of the annual fee